Want to see AVXL full AI Analyst Report?
Anavex Life Sciences (AVXL) Ratios
Anavex Life Sciences Ratios
AVXL's free cash flow for Q3 2026 was $-13.54M. For the 2026 fiscal year, AVXL's free cash flow was increased by $0.00 and operating cash flow was $-13.54M. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.60 | 8.86 | 12.32 | 14.95 | 14.97 |
| Quick Ratio | 11.60 | 8.86 | 12.32 | 14.95 | 14.97 |
| Cash Ratio | 11.47 | 8.64 | 12.05 | 14.60 | 14.09 |
| Solvency Ratio | -5.18 | -2.81 | -4.01 | -5.02 | -0.04 |
| Operating Cash Flow Ratio | -4.36 | -2.01 | -2.22 | -2.37 | -2.81 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 94.87M | $ 120.26M | $ 141.85M | $ 142.49M | $ 150.82M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.13 | 1.09 | 1.07 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -57.85 | -54.17 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | -57.84 | -53.84 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Net Debt to EBITDA | 2.21 | 3.07 | 2.71 | 2.93 | 4.07 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.01% | 100.75% | 100.71% |
| EBT Per EBIT | 90.21% | 81.32% | 85.19% | 93.40% | 89.79% |
| Return on Assets (ROA) | -44.67% | -31.72% | -30.77% | -31.42% | -23.46% |
| Return on Equity (ROE) | -48.89% | -35.76% | -33.49% | -33.67% | -25.14% |
| Return on Capital Employed (ROCE) | -54.19% | -43.97% | -39.31% | -35.78% | -27.80% |
| Return on Invested Capital (ROIC) | -54.19% | -43.97% | -38.40% | -1.38% | -27.79% |
| Return on Tangible Assets | -44.67% | -31.72% | -30.77% | -31.42% | -23.46% |
| Earnings Yield | -6.11% | -9.07% | -9.09% | -6.04% | -3.03% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.46 | -0.37 | -0.35 | -0.32 | -0.44 |
| Free Cash Flow Per Share | -0.46 | -0.37 | -0.35 | -0.32 | -0.44 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -6059466.00 | -7595918.50 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -6059466.00 | -7595918.50 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -5.14% | -6.50% | -5.32% | -3.05% | -2.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -16.48 | -11.03 | -11.00 | -16.54 | -33.05 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 8.00 | 3.94 | 3.68 | 5.57 | 8.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -19.44 | -15.39 | -18.81 | -32.75 | -41.24 |
| Price-to-Operating Cash Flow Ratio | -19.44 | -15.39 | -18.81 | -32.75 | -41.24 |
| Price-to-Earnings Growth (PEG) Ratio | -4.29 | 0.83 | 3.41 | -1.12 | -1.65 |
| Enterprise Value Multiple | -14.16 | -7.95 | -6.66 | -12.65 | -29.45 |
| Enterprise Value | 656.50M | 341.91M | 371.59M | 644.55M | 1.10B |
| EV to EBITDA | -14.16 | -7.95 | -6.66 | -12.65 | -29.45 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -16.81 | -11.10 | -13.37 | -26.59 | -36.23 |
| EV to Operating Cash Flow | -16.81 | -11.10 | -13.37 | -26.59 | -36.23 |
| Tangible Book Value Per Share | 1.11 | 1.44 | 1.78 | 1.85 | 2.16 |
| Shareholders’ Equity Per Share | 1.11 | 1.44 | 1.78 | 1.85 | 2.16 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | -0.01 | -0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.01 | 1.01 |
| Interest Burden | 1.00 | 1.00 | 0.90 | 0.93 | 0.89 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.84 | 0.72 | 0.58 | 0.51 | 0.80 |
Currency in USD